Statistics for Apellis Pharmaceuticals (id:7243 APLS)

Valuation metrics

Market cap

3.45B

Enterprise value

3.49B

Trailing P/E (ttm)

-6.95

Forward P/E

-33.04

PEG ratio

-33.04

Price/Sales (ttm)

4.83

Price/Book (mrq)

14.28

Enterprise Value/Revenue

4.88

Enterprise Value/EBITDA

-15.74

Overview

Shares outstanding

124.39M

Float

84.64M

Shares short

20.79M

% Held by insiders

0.14%

% Held by institutions

0.97%

Average volume (10 days)

4.44M

Average volume (90 days)

Price summary

52-Week low

24.34

52-Week high

73.80

52-Week change

-56.99%

Beta

0.87

50-Day moving average

29.23

200-Day moving average

42.54

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-34.97%

Operating margin

-24.02%

Operational effectiveness

Return on assets

-16.23%

Return on equity

-106.56%

Income statement

Revenue (ttm)

5.81

Revenue per share (ttm)

5.81

Quarterly revenue growth (yoy)

Gross profit (ttm)

338.08M

EBITDA

-221,507,008.00

Net income to common (ttm)

-250,100,992.00

Diluted EPS (ttm)

-2.03

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

403.69M

Total cash per share (mrq)

3.24

Total debt (mrq)

470.45M

Total Debt/Equity (mrq)

198.40

Current ratio (mrq)

436.00%

Book value per share (mrq)

1.94

Cash flow

Cash flow statement

-205,100,992.00

Levered free cash flow (LFCF)

-140,212,000.00